Press Release May 11 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Dexamethasone Tablets USP, one milligram. This medication is used to treat various medical conditions including arthritis and cancer. The tablets will be manufactured at the company's facility in Baddi, Himachal Pradesh. The press release highlights that the product had annual sales of a significant amount in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 09 2024
- Press Release May 04 2024
- Press Release Apr 26 2024
- Press Release Apr 23 2024
- Press Release Apr 22 2024
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release May 17 2024
- Press Release May 22 2024
- Press Release May 24 2024
- Press Release Jun 14 2024
- Press Release Jun 28 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences